Targeting BCL-2-like Proteins to Kill Cancer Cells

Trends in Cancer

Volumn 2, Issue 8, 2016, Pages 443-460

  Cory, Suzanne ^a,b   Roberts, Andrew W ^a,b,c,d   Colman, Peter M ^a,b   Adams, Jerry M ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d VICTORIAN COMPREHENSIVE CANCER CENTRE   (Australia)

Author keywords

apoptosis; BCL 2 protein family; BH3 mimetic drugs; chronic lymphocytic leukemia; drug development; mitochondrial membrane

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; A 1155463; ANTINEOPLASTIC AGENT; BCL 2 LIKE PROTEIN; BCL2 RELATED PROTEIN A1; BH3 PROTEIN; BIM PROTEIN; CASPASE; CYTOCHROME C; DOCETAXEL; ERLOTINIB; NAVITOCLAX; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; PROTEIN NOXA; PROTEIN P53; RITUXIMAB; UNCLASSIFIED DRUG; VENETOCLAX; WEHI 539; ANILINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL OUTCOME; CONTROLLED CLINICAL TRIAL (TOPIC); DIMERIZATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; GENE MUTATION; HUMAN; IN VIVO STUDY; LICENSING; MONOTHERAPY; NEOPLASM; NONHUMAN; ONCOGENE; PATIENT; PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 84995426869     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.07.001     Document Type: Review

References (147)

1. 1 Kerr, J.F.R., et al. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26 (1972), 239–257.
2. 2 Anderson, M.A., et al. Targeting BCL2 for the treatment of lymphoid malignancies. Semin. Hematol. 51 (2014), 219–227.
3. 3 Tam, C.S., et al. Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia. Semin. Oncol. 43 (2016), 274–279.
4. 4 Sarosiek, K.A., Letai, A., Directly targeting the mitochondrial pathway of apoptosis for cancer therapy with BH3 mimetics: recent successes, current challenges and future promise. FEBS J., 2016 Mar 21. (epub ahead of print).
5. 5 Strasser, A., et al. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 30 (2011), 3667–3683.
6. 6 Czabotar, P.E., et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15 (2014), 49–63.
7. 7 Delbridge, A.R., et al. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat. Rev. Cancer 16 (2016), 99–109.
8. 8 Moldoveanu, T., et al. Many players in BCL-2 family affairs. Trends Biochem. Sci. 39 (2014), 101–111.
9. 9 Shamas-Din, A., et al. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb. Perspect Biol., 5, 2013, a008714.
10. 10 Correia, C., et al. Emerging understanding of Bcl-2 biology: implications for neoplastic progression and treatment. Biochim. Biophys. Acta 1853 (2015), 1658–1671.
11. 11 Fukuhara, S., Rowley, J.D., Chromosome 14 translocations in non-Burkitt lymphomas. Int. J. Cancer 22 (1978), 14–21.
12. 12 Tsujimoto, Y., et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226 (1984), 1097–1099.
13. 13 Cleary, M.L., Sklar, J., Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc. Natl. Acad. Sci. U.S.A. 82 (1985), 7439–7443.
14. H on chromosome 14 and near a transcriptional unit on 18. Cell 41 (1985), 899–906.
15. 15 Vaux, D.L., et al. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335 (1988), 440–442.
16. 16 McDonnell, T.J., et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57 (1989), 79–88.
17. 17 Strasser, A., et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl. Acad. Sci. U.S.A. 88 (1991), 8661–8665.
18. 18 Sentman, C.L., et al. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67 (1991), 879–888.
19. 19 Strasser, A., et al. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 67 (1991), 889–899.
20. 20 Strasser, A., et al. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348 (1990), 331–333.
21. 21 Johnson, N.A., et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 114 (2009), 2273–2279.
22. 22 Evan, G.I., et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69 (1992), 119–128.
23. 23 McDonnell, T.J., Korsmeyer, S.J., Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 349 (1991), 254–256.
24. 24 Strasser, A., et al. Eμ-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. Oncogene 8 (1993), 1–9.
25. 25 Egle, A., et al. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 103 (2004), 2276–2283.
26. 26 Cimmino, A., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U.S.A. 102 (2005), 13944–13949.
27. 27 Hengartner, M.O., et al. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 356 (1992), 494–499.
28. 28 Vaux, D.L., et al. Prevention of programmed cell death in Caenorhabditis elegans by human bcl-2. Science 258 (1992), 1955–1957.
29. 29 Hengartner, M.O., Horvitz, H.R., C.elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 76 (1994), 665–676.
30. 30 Lindsten, T., et al. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol. Cell 6 (2000), 1389–1399.
31. 31 Kutuk, O., Letai, A., Regulation of Bcl-2 family proteins by posttranslational modifications. Curr. Mol. Med. 8 (2008), 102–118.
32. L, an inhibitor of programmed cell death. Nature 381 (1996), 335–341.
33. 33 Suzuki, M., et al. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 103 (2000), 645–654.
34. 34 Kvansakul, M., Hinds, M.G., The Bcl-2 family: structures, interactions and targets for drug discovery. Apoptosis 20 (2015), 136–150.
35. 35 Hinds, M.G., et al. Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death Differ. 14 (2007), 128–136.
36. 36 Chou, J.J., et al. Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell 96 (1999), 615–624.
37. 37 McDonnell, J.M., et al. Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists. Cell 96 (1999), 625–634.
38. L-Bak peptide complex: recognition between regulators of apoptosis. Science 275 (1997), 983–986.
39. L/Bim fragment complex: implications for Bim function. Immunity 19 (2003), 341–352.
40. 40 Chen, L., et al. Differential targeting of pro-survival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17 (2005), 393–403.
41. 41 Kuwana, T., et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell 17 (2005), 525–535.
42. 42 Lee, E.F., et al. The functional differences between pro-survival and pro-apoptotic B cell lymphoma 2 (Bcl-2) proteins depend on structural differences in their Bcl-2 homology 3 (BH3) domains. J. Biol. Chem. 289 (2014), 36001–36017.
43. 43 Willis, S.N., et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 19 (2005), 1294–1305.
44. 44 Willis, S.N., et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315 (2007), 856–859.
45. 45 Edlich, F., et al. Bcl-x(L) Retrotranslocates Bax from the mitochondria into the cytosol. Cell 145 (2011), 104–116.
46. 46 Czabotar, P.E., et al. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 152 (2013), 519–531.
47. 47 Moldoveanu, T., et al. BID-induced structural changes in BAK promote apoptosis. Nat. Struct. Mol. Biol. 20 (2013), 589–597.
48. 48 Brouwer, J.M., et al. Bak core and latch domains separate during activation, and freed core domains form symmetric homodimers. Mol. Cell 55 (2014), 938–946.
49. 49 Westphal, D., et al. Apoptotic pore formation is associated with in-plane insertion of Bak or Bax central helices into the mitochondrial outer membrane. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), E4076–E4085.
50. 50 Robin, A.Y., et al. Crystal structure of Bax bound to the BH3 peptide of Bim identifies important contacts for interaction. Cell Death Dis., 6, 2015, e1809.
51. 51 Dewson, G., et al. To trigger apoptosis Bak exposes its BH3 domain and homo-dimerizes via BH3:grooove interactions. Mol. Cell 30 (2008), 369–380.
52. 52 Dewson, G., et al. Bax dimerizes via a symmetric BH3:groove interface during apoptosis. Cell Death Differ. 19 (2012), 661–670.
53. 53 Beroukhim, R., et al. The landscape of somatic copy-number alteration across human cancers. Nature 463 (2010), 899–905.
54. 54 Tagawa, H., et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 24 (2005), 1348–1358.
55. 55 Garrison, S.P., et al. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol. Cell Biol. 28 (2008), 5391–5402.
56. 56 Richter-Larrea, J.A., et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 116 (2010), 2531–2542.
57. 57 van Delft, M.F., et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10 (2006), 389–399.
58. 58 Lessene, G., et al. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov. 7 (2008), 989–1000.
59. 59 Oltersdorf, T., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005), 677–681.
60. 60 Tse, C., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68 (2008), 3421–3428.
61. 61 Lee, E.F., et al. Crystal structure of ABT-737 complexed with Bcl-x(L): implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ. 14 (2007), 1711–1713.
62. 62 Souers, A.J., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19 (2013), 202–208.
63. 63 Roberts, A.W., et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30 (2012), 488–496.
64. 64 Wilson, W.H., et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11 (2010), 1149–1159.
65. 65 Mason, K.D., et al. Programmed anuclear cell death delimits platelet life span. Cell 128 (2007), 1173–1186.
66. 66 Zhang, H., et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 14 (2007), 943–951.
67. 67 Vandenberg, C.J., Cory, S., ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 121 (2013), 2285–2288.
68. 68 Merino, D., et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 119 (2012), 5807–5816.
69. 69 Rooswinkel, R.W., et al. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis., 3, 2012, e366.
70. 70 Del Gaizo Moore, V., et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Invest. 117 (2007), 112–121.
71. 71 Certo, M., et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9 (2006), 351–365.
72. 72 Chonghaile, T.N., et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334 (2011), 1129–1133.
73. 73 Vo, T.T., et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151 (2012), 344–355.
74. 74 Konopleva, M., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10 (2006), 375–388.
75. 75 Mason, K.D., et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 17961–17966.
76. 76 Oakes, S.R., et al. Breast cancer special feature: sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc. Natl. Acad. Sci. U.S.A. 109 (2012), 2766–2771.
77. + lymphoid malignancies. Br. J. Haematol 170 (2015), 669–678.
78. 78 Kitada, S., et al. Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 21 (2002), 3459–3474.
79. 79 Mason, K.D., et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 23 (2009), 2034–2041.
80. 80 Kipps, T.J., et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk. Lymphoma 56 (2015), 2826–2833.
81. 81 Gandhi, L., et al. Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 29 (2011), 909–916.
82. 82 Vlahovic, G., et al. A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. Invest. New Drugs 32 (2014), 976–984.
83. 83 Cleary, J.M., et al. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest. New Drugs 32 (2014), 937–945.
84. 84 Tolcher, A.W., et al. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study. Cancer Chemother. Pharmacol. 76 (2015), 1041–1049.
85. 85 Tolcher, A.W., et al. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 76 (2015), 1025–1032.
86. 86 Roberts, A.W., et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374 (2016), 311–322.
87. 87 Stilgenbauer, S., et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 17 (2016), 768–778.
88. 88 Stilgenbauer, S., Zenz, T., Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Educ. Program 2010 (2010), 481–488.
89. 89 Zenz, T., et al. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 119 (2012), 4101–4107.
90. 90 Touzeau, C., et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia 28 (2014), 210–212.
91. 91 Vogler, M., et al. BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 117 (2011), 7145–7154.
92. 92 Anderson, M.A., et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood 127 (2016), 3215–3224.
93. 93 Matulis, S.M., et al. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia 30 (2016), 1086–1093.
94. 94 Leverson, J.D., et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci. Transl. Med., 7, 2015, 279ra240.
95. 95 Cervantes-Gomez, F., et al. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin. Cancer Res. 21 (2015), 3705–3715.
96. 96 Li, Y., et al. FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. Oncogene, 2016 May 9. (epub ahead of print).
97. 97 Ma, S., et al. Deep and durable responses following venetoclax (ABT-199/GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from a phase 1b study. Blood, 126(23), 2015 abstract 830.
98. 98 Pan, R., et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 4 (2014), 362–375.
99. 99 Chan, S.M., et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat. Med. 21 (2015), 178–184.
100. 100 DiNardo, C., et al. A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ to 65 years and not eligible for standard induction therapy. Blood, 126(23), 2015 abstract 327.
101. 101 Pollyea, D.A., et al. Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients > = 65 years ineligible for standard induction therapy. J. Clin. Oncol., 34(15), 2016 suppl: abstract 7009.
102. 102 Vaillant, F., et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 24 (2013), 120–129.
103. 103 Chen, J., et al. Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression. J. Med. Chem. 55 (2012), 8502–8514.
104. 104 Perez, H.L., et al. Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists. Bioorg. Med. Chem. Lett. 22 (2012), 3946–3950.
105. 105 Lessene, G., et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat. Chem. Biol. 9 (2013), 390–397.
106. 106 Tao, Z.F., et al. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS Med. Chem. Lett. 5 (2014), 1088–1093.
107. 107 Zhang, H., et al. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer. Mol. Cancer, 14, 2015, 126.
108. 108 Amundson, S.A., et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60 (2000), 6101–6110.
109. 109 Kasai, S., et al. Haploinsufficiency of Bcl-x leads to male-specific defects in fetal germ cells: differential regulation of germ cell apoptosis between the sexes. Dev. Biol. 264 (2003), 202–216.
110. 110 Rudin, C.M., et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18 (2012), 3163–3169.
111. 111 Anonymous (2011) Brentuximab vedotin. Drugs RD 11, 85-95.
112. 112 Girish, S., et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother. Pharmacol. 69 (2012), 1229–1240.
113. 113 Kaufmann, S.H., et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 91 (1998), 991–1000.
114. 114 Zhang, B., et al. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99 (2002), 1885–1893.
115. 115 Zhang, H., et al. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 30 (2011), 1963–1968.
116. 116 Song, L., et al. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol. Ther. 4 (2005), 267–276.
117. 117 Xiao, Y., et al. MCL-1 is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor. Mol. Cancer Ther. 14 (2015), 1837–1847.
118. 118 Meynet, O., et al. Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice. Blood 122 (2013), 2402–2411.
119. 119 Leverson, J.D., et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis., 6, 2015, e1590.
120. 120 Yecies, D., et al. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 115 (2010), 3304–3313.
121. 121 Glaser, S., et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 26 (2012), 120–125.
122. 122 Kelly, G.L., et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 28 (2014), 58–70.
123. 123 Grabow, S., et al. MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice. Blood 124 (2014), 3939–3946.
124. 124 Koss, B., et al. Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia. Blood 122 (2013), 1587–1598.
125. 125 Spinner, S., et al. Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance. Leukemia, 2016 Mar 8. (epub ahed of print).
126. 126 Thomas, R.L., et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 27 (2013), 1365–1377.
127. 127 Vick, B., et al. Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology 49 (2009), 627–636.
128. 128 Arbour, N., et al. Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. J. Neurosci. 28 (2008), 6068–6078.
129. 129 Gavathiotis, E., et al. Direct and selective small-molecule activation of proapoptotic BAX. Nat. Chem. Biol. 8 (2012), 639–645.
130. 130 Zhao, G., et al. Activation of the proapoptotic Bcl-2 protein Bax by a small molecule induces tumor cell apoptosis. Mol. Cell Biol. 34 (2014), 1198–1207.
131. 131 Iyer, S., et al. Identification of an activation site in Bak and mitochondrial Bax triggered by antibodies. Nat. Commun., 7, 2016, 11734.
132. 132 Echeverry, N., et al. Intracellular localization of the BCL-2 family member BOK and functional implications. Cell Death Differ. 20 (2013), 785–799.
133. 133 Llambi, F., et al. BOK is a non-canonical BCL-2 family effector of apoptosis regulated by ER-associated degradation. Cell 165 (2016), 421–433.
134. 134 Kvansakul, M., et al. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ. 15 (2008), 1564–1571.
135. 135 Lee, E.F., et al. High-resolution structural characterization of a helical alpha/beta-peptide foldamer bound to the anti-apoptotic protein Bcl-xL. Angew. Chem. Int. Ed Engl. 48 (2009), 4318–4322.
136. 136 Billen, L.P., et al. Bcl-XL inhibits membrane permeabilization by competing with Bax. PLoS Biol., 6, 2008, e147.
137. 137 Gavathiotis, E., et al. BAX activation is initiated at a novel interaction site. Nature 455 (2008), 1076–1081.
138. 138 Gavathiotis, E., et al. BH3-triggered structural reorganization drives the activation of proapoptotic BAX. Mol. Cell 40 (2010), 481–492.
139. 139 O'Neill, K.L., et al. Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane. Genes Dev. 30 (2016), 973–988.
140. 140 Bleicken, S., et al. Molecular details of Bax activation, oligomerization, and membrane insertion. J. Biol. Chem. 285 (2010), 6636–6647.
141. 141 Zhang, Z., et al. Bax forms an oligomer via separate, yet interdependent, surfaces. J. Biol. Chem. 285 (2010), 17614–17627.
142. 142 Oh, K.J., et al. Conformational changes in BAK, a pore-forming proapoptotic Bcl-2 family member, upon membrane insertion and direct evidence for the existence of BH3-BH3 contact interface in BAK homo-oligomers. J. Biol. Chem. 285 (2010), 28924–28937.
143. 143 Annis, M.G., et al. Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J. 24 (2005), 2096–2103.
144. 144 Cory, S., Adams, J.M., Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 8 (2005), 5–6.
145. 145 Gerecitano, J.F., et al. A phase 1 study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma. Blood, 126, 2015 abstract 254.
146. 146 Kumar, S.K., et al. Safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory multiple myeloma: phase 1 preliminary results. Blood, 126, 2015 abstract 4219.
147. 147 Konopleva, M., et al. A phase 2 study of ABT-199 (GDC-0199) in patients with acute myelogenous leukemia. Blood, 124, 2014 abstract 118.